Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd.

Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd. was formerly known as Zhejiang Huangyan Xinhua Pharmaceutical Chemical Factory founded in 1998. In 2003, it was moved to Linhai Park, a national chemical bulk drug base, and was renamed Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd. Its current production base covers an area of 100,000 square meters, with a workshop area of 25,000 square meters and has a registered capital of 342,263,700 yuan. The company's subsidiaries include Hong Kong IMAX, Ireland IMAX and Shanghai IMAX. It is a comprehensive Sino-foreign joint venture integrating research and development of bulk drugs, pharmaceutical intermediates and preparations.

The company was acquired by the listed company Starry in 2018. Since the establishment of the factory, the company has focused on contrast agent bulk drugs as its core business and continuously improved its own process of iohexol and iopamidol. Up to now, iohexol and iopamidol have become the best selling products of the company. At present, the company is focusing on research and development and production of high-quality contrast agent bulk drugs, with a view to developing a full range of non-patented contrast agent bulk drugs. With its solid science and technology foundation and perfect execution capability, the company is capable of supplying a large number of products conforming to global quality standards. In addition, the company also provides technical and regulatory support to customers. Relying on reliable logistics distribution and an operation mode that fully conforms to China's drug production and management standards, the company has established long-term cooperative relations with customers.

BACK